Cases & Deals

  • Home
  • Practices
  • Nanjing Legend Biotech establishes global patent portfolio for CAR-T therapeutics

Share

Nanjing Legend Biotech establishes global patent portfolio for CAR-T therapeutics

February 2021

Clients Nanjing Legend Biotech Co., Ltd et al

Jones Day represents Nanjing Legend Biotech Co., Ltd et al in the development and prosecution of global patent portfolios related to chimeric antigen receptor T cell (CAR-T) and other cellular therapeutics, including certain clinical trial candidates.

Contacts

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.